Alveron Pharma Commences Clinical Trial Of New Intracranial Haemorrhage DrugVicky Coghlan2024-11-28T14:47:31+00:00March 31st, 2023|BioCity Nottingham, News|
Myconeos Innovate UK Smart Grant SuccessVicky Coghlan2023-03-28T14:48:14+01:00March 28th, 2023|BioCity Nottingham, News|
NanoSyrinx Joins Life Sciences Incubator In NottinghamAmy Cotterill2024-11-28T14:47:44+00:00March 27th, 2023|Accelerator, BioCity Nottingham, Investment, News|
Life Sciences Investing: Pioneer Group Reinvests In Biotech Firm NuVisionVicky Coghlan2024-11-28T14:48:12+00:00March 9th, 2023|Accelerator, BioCity Nottingham, Investment, News|
New Platform Set To Accelerate Early-Stage Targeted Protein Degradation ProgrammesVicky Coghlan2024-11-28T14:07:30+00:00March 7th, 2023|Article, BioCity Nottingham, News|
Pioneer Group Tenant MIP Discovery Secure Funding From Bill & Melinda Gates FoundationVicky Coghlan2023-04-03T14:24:52+01:00February 16th, 2023|Colworth Park, News|
£20m Series A Funding For Two Pioneer Group Accelerator Programme GraduatesVicky Coghlan2023-03-09T15:14:09+00:00February 15th, 2023|Accelerator, Headline Article, News|
Pioneer Group Announce Lead Investment In Selentus ScienceVicky Coghlan2024-11-28T14:49:26+00:00February 7th, 2023|BioCity Nottingham, Investment, News|
AbbVie And Pioneer Group Name NanoSyrinx As The Winner Of The 2022 AbbVie UK Golden Ticket ProgrammeGemma Cann2025-03-20T15:50:40+00:00September 27th, 2022|Accelerator, News|
RoslinCT And Lykan Bioscience Combine To Create Leading Advanced Cell Therapy CDMOGemma Cann2024-11-28T14:50:04+00:00August 9th, 2022|Edinburgh Technopole, News|
